🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This was an exploratory, randomized, subject- and investigator-blind, place...
Status
Terminated
Location
Novartis Investigative Site
Start Date
2019-05-21
Trial ID
NCT03810183
A randomized, multicenter, double-blind, placebo- controlled parallel-group...
Status
Completed
Location
Novartis Investigative Site
Start Date
2017-11-01
Trial ID
NCT03215758
The purpose of this study is to determine whether QAW039 is safe and has be...
Status
Completed
Location
Novartis Investigative Site
Start Date
2013-06
Trial ID
NCT01785602
This study will assess the safety, efficacy and pharmacokinetics of QAW039 ...
Status
Completed
Location
Novartis Investigative Site
Start Date
2010-11
Trial ID
NCT01253603
The overall purpose of this study was to determine the efficacy of fevipipr...
Status
Terminated
Location
Novartis Investigative Site
Start Date
2018-12-13
Trial ID
NCT03629249
Treatments Being Tested
This study will assess the safety and efficacy of QAW039 when added to curr...
Status
Completed
Location
Novartis Investigative Site
Start Date
2012-02
Trial ID
NCT01545726
This study aims to demonstrate a clinically significant improvement in Forc...
Status
Completed
Location
Novartis Investigative Site
Start Date
2011-08
Trial ID
NCT01437735
Treatments Being Tested
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 15...
Status
Completed
Location
Novartis Investigative Site
Start Date
2019-03-26
Trial ID
NCT03681093
Treatments Being Tested
This is an exploratory, randomized, subject- and investigator-blinded, plac...
Status
Withdrawn
Location
Multiple Locations
Start Date
2019-10-15
Trial ID
NCT03989635
Treatments Being Tested
A randomized, multicenter, double-blind, placebo- controlled parallel-group...
Status
Completed
Location
Novartis Investigative Site
Start Date
2017-10-31
Trial ID
NCT03226392